サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1631377

人工関節感染症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Prosthetic Joint Infections Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 227 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
人工関節感染症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年01月09日
発行: Persistence Market Research
ページ情報: 英文 227 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の人工関節感染症治療の市場規模は、2025年に1,154億米ドルになるとみられ、2025年～2032年の予測期間に5.0%のCAGRで拡大し、2032年には1,621億米ドルに達すると予測されています。

人工関節感染症（PJI）治療には、人工関節置換術に伴う感染症に対処することを目的とした治療法や抗生物質が含まれます。PJIは、黄色ブドウ球菌やカンジダ種などの病原菌によって引き起こされることが多い深刻な合併症です。この市場を牽引しているのは、人工関節置換術の件数の増加、糖尿病や関節炎などの慢性疾患の有病率の上昇、診断・治療技術の進歩などです。さらに、革新的な薬剤や併用療法の開発が市場の成長を促進しています。

人口の高齢化による人工関節置換術の件数の増加、肥満や変形性関節症の有病率の上昇など、いくつかの要因が世界の人工関節感染治療市場の成長を後押ししています。PCRベースの検査などの診断技術の進歩により、PJIの早期発見率が向上し、治療需要が高まっています。院内感染に対する意識の高まりや、標的治療薬や先進ドラッグデリバリーシステムの開発が、市場の成長をさらに後押ししています。

人工関節感染症治療市場は、特に新しい抗生物質や併用療法の研究開発が進んでいることから、大きな成長機会をもたらしています。革新的な治療ソリューションを開発するための製薬企業とヘルスケア機関の提携は、さらなる成長の可能性を引き出すと期待されます。ヘルスケア・インフラ投資が増加し、PJI治療に対する認識が高まっている新興国での拡大も、有望な成長の道を提供します。AIを活用した診断ツールと遠隔医療プラットフォームの統合により、早期診断と治療のアドヒアランスが強化され、市場拡大に寄与する可能性があります。

当レポートでは、世界の人工関節感染症治療市場について調査し、薬剤別、感染症別、別、病原体別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要な市場動向

第4章 付加価値の洞察

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 世界市場の需要（10億米ドル）分析（2019年～2024年）および予測（2025年～2032年）

第7章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、薬剤別

第8章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、感染症別

第9章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、病原体別

第10章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、投与経路別

第11章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、流通チャネル別

第12章 世界の人工関節感染症治療市場分析（2019年～2024年）および予測（2025年～2032年）、地域別

第13章 北米の市場分析（2019年～2024年）および予測（2025年～2032年）

第14章 ラテンアメリカの市場分析（2019年～2024年）および予測（2025年～2032年）

第15章 欧州の市場分析（2019年～2024年）および予測（2025年～2032年）

第16章 東アジアの市場分析（2019年～2024年）および予測（2025年～2032年）

第17章 南アジアの市場分析（2019年～2024年）および予測（2025年～2032年）

第18章 オセアニアの市場分析（2019年～2024年）および予測（2025年～2032年）

第19章 中東・アフリカの市場分析（2019年～2024年）および予測（2025年～2032年）

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析（%）
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 主要開発分析
  • 主要参入企業によるブランディングとプロモーション戦略
  • 競合の詳細
    • Pfizer Inc.
    • Novartis AG
    • Mylan N.V.
    • Teva Pharmaceuticals
    • Merck & Co.
    • Eli Lilly & Company
    • AstraZeneca plc.
    • Lupin Limited
    • Dr Reddys Laboratories
    • Aurobindo Pharma Ltd
    • GSK plc.
    • Sun Pharmaceutical Industries Ltd.
    • Cipla ltd.

第22章 使用される仮定と頭字語

第23章 調査手法

目次
Product Code: PMRREP29797

Persistence Market Research has recently released a comprehensive report on the global Prosthetic Joint Infection (PJI) Treatment Market, providing an in-depth analysis of key market dynamics, including drivers, emerging trends, opportunities, and challenges. This report offers valuable insights into the market landscape, helping stakeholders make informed decisions about growth strategies.

Key Insights:

  • Prosthetic Joint Infection Treatment Market Size (2025E): USD 115.4 Bn
  • Projected Market Value (2032F): USD 162.1 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.0%

Prosthetic Joint Infection Treatment Market - Report Scope:

Prosthetic Joint Infection (PJI) treatment involves therapies and antibiotics aimed at combating infections associated with joint replacement surgeries. PJI is a serious complication often caused by pathogens such as Staphylococcus aureus or Candida species. This market is driven by the rising number of joint replacement surgeries, increasing prevalence of chronic conditions such as diabetes and arthritis, and advancements in diagnostic and treatment techniques. Furthermore, the development of innovative drugs and combination therapies is fueling market growth.

Market Growth Drivers:

Several factors drive the growth of the global Prosthetic Joint Infection Treatment Market, including the rising number of joint replacement surgeries due to an aging population and increased prevalence of obesity and osteoarthritis. Technological advancements in diagnostics, such as PCR-based testing, have improved early detection rates of PJI, thus driving demand for treatment. Increasing awareness about hospital-acquired infections and the development of targeted therapies and advanced drug delivery systems are further bolstering market growth.

Market Restraints:

Despite its promising growth, the PJI treatment market faces challenges such as high treatment costs and limited availability of effective therapies in low-income regions. Moreover, the growing incidence of antibiotic resistance poses a significant barrier to effective treatment, necessitating the development of new antibiotics and alternative therapeutic approaches. Regulatory hurdles in approving new drugs and therapies for PJI also act as market constraints.

Market Opportunities:

The Prosthetic Joint Infection Treatment Market presents substantial growth opportunities, particularly with the ongoing research and development of new antibiotics and combination therapies. Partnerships between pharmaceutical companies and healthcare institutions to develop innovative treatment solutions are expected to unlock further growth potential. Expansion in emerging economies with increasing healthcare infrastructure investment and rising awareness of PJI treatments also provides a promising growth avenue. The integration of AI-driven diagnostic tools and telemedicine platforms could enhance early diagnosis and treatment adherence, contributing to market expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Prosthetic Joint Infection Treatment Market?
  • Which drug classes and pathogens dominate the market?
  • How are technological advancements shaping the competitive landscape of the market?
  • Who are the key players, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the PJI treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global Prosthetic Joint Infection Treatment Market, including Pfizer Inc., Novartis AG, and Mylan N.V., are focusing on R&D initiatives, strategic collaborations, and product innovations to strengthen their market positions. Companies are actively investing in developing novel antibiotics to combat drug-resistant strains and enhance treatment outcomes. Expansion into emerging markets, along with partnerships with hospitals and diagnostic centers, is a key strategy for market penetration. Emphasis on affordability, safety, and compliance with regulatory standards ensures long-term success for these players in the competitive landscape.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceuticals
  • Merck & Co.
  • Eli Lilly & Company
  • AstraZeneca PLC
  • Lupin Limited
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma Ltd.
  • GSK PLC
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.

Prosthetic Joint Infection Treatment Industry Research by Category:

By Drug:

  • Aminoglycosides
  • Glycopeptides
  • Rifamycin
  • Lincosamide
  • Penicillin
  • Other Antibiotics

By Infection:

  • Pre-operative Infection
  • Post-operative Infection

By Route of Administration:

  • Oral
  • Intravenous

By Pathogen:

  • Staphylococcus Aureus
  • Coagulase-negative Staphylococcus
  • Candida Species
  • Enterococcus Species
  • Other Pathogens

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply-Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Value Added Insights

  • 4.1. Product Adoption Analysis
  • 4.2. Product USPs/Features Analysis, By Brands
  • 4.3. Regulatory Landscape, By Country
  • 4.4. Recent Product Approval/Launches
  • 4.5. Disease Epidemiology
  • 4.6. Porter's Analysis
  • 4.7. PESTLE Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Unmet Needs

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global Healthcare Expenditure Outlook
    • 5.1.2. Global Pharmaceutical Market Outlook
    • 5.1.3. Global Surgical Site Infection Control Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Rate of Joint Surgery
    • 5.2.2. Increase in Research and Development
    • 5.2.3. Strategic Collaborations among players
    • 5.2.4. Cost of Product
    • 5.2.5. Business Expansions
    • 5.2.6. Frequency of Product Approval
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019 - 2024 and Forecast, 2025 - 2032

  • 6.1. Historical Market Value (US$ Bn) Analysis, 2019 - 2024
  • 6.2. Current and Future Market Size (US$ Bn) Projections, 2025 - 2032
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis
  • 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Drug

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019 - 2024
  • 7.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2025 - 2032
    • 7.3.1. Aminoglycosides
    • 7.3.2. Glycopeptides
    • 7.3.3. Rifamycin
    • 7.3.4. Lincosamide
    • 7.3.5. Penicillin
    • 7.3.6. Other Antibiotics
  • 7.4. Market Attractiveness Analysis By Drug

8. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Infection

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Infection, 2019 - 2024
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Infection, 2025 - 2032
    • 8.3.1. Pre-operative Infection
    • 8.3.2. Post-operative Infection
  • 8.4. Market Attractiveness Analysis By Infection

9. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Pathogen

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis By Pathogen, 2019 - 2024
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Pathogen, 2025 - 2032
    • 9.3.1. Staphylococcus aureus
    • 9.3.2. Coagulase-negative Staphylococcus
    • 9.3.3. Candida species
    • 9.3.4. Enterococcus species
    • 9.3.5. Other Pathogens
  • 9.4. Market Attractiveness Analysis By Pathogen

10. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2019 - 2024
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2025 - 2032
    • 10.3.1. Oral
    • 10.3.2. Intravenous
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019 - 2024
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2025 - 2032
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Drug Stores
    • 11.3.4. Online Sales
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019 - 2024 and Forecast 2025 - 2032, by Region

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019 - 2024
  • 12.3. Current and Future Market Size (US$ Bn) Analysis Forecast By Region, 2025 - 2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 13.3.1. By Country
      • 13.3.1.1. United States
      • 13.3.1.2. Canada
    • 13.3.2. By Drug
    • 13.3.3. By Infection
    • 13.3.4. By Pathogen
    • 13.3.5. By Route of Administration
    • 13.3.6. By Distribution Channel
  • 13.4. Market Attractiveness Analysis By Region
    • 13.4.1. By Country
    • 13.4.2. By Drug
    • 13.4.3. By Infection
    • 13.4.4. By Pathogen
    • 13.4.5. By Route of Administration
    • 13.4.6. By Distribution Channel
  • 13.5. Market trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. United States Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug
        • 13.8.1.2.2. By Infection
        • 13.8.1.2.3. By Pathogen
        • 13.8.1.2.4. By Route of Administration
        • 13.8.1.2.5. By Distribution Channel
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug
        • 13.8.2.2.2. By Infection
        • 13.8.2.2.3. By Pathogen
        • 13.8.2.2.4. By Route of Administration
        • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug
    • 14.3.3. By Infection
    • 14.3.4. By Pathogen
    • 14.3.5. By Route of Administration
    • 14.3.6. By Distribution Channel
  • 14.4. Market Attractiveness Analysis By Region
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Infection
    • 14.4.4. By Pathogen
    • 14.4.5. By Route of Administration
    • 14.4.6. By Distribution Channel
  • 14.5. Market trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Infection
        • 14.8.1.2.3. By Pathogen
        • 14.8.1.2.4. By Route of Administration
        • 14.8.1.2.5. By Distribution Channel
    • 14.8.2. Mexico Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Infection
        • 14.8.2.2.3. By Pathogen
        • 14.8.2.2.4. By Route of Administration
        • 14.8.2.2.5. By Distribution Channel
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug
        • 14.8.3.2.2. By Infection
        • 14.8.3.2.3. By Pathogen
        • 14.8.3.2.4. By Route of Administration
        • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. France
      • 15.3.1.3. Spain
      • 15.3.1.4. Russia
      • 15.3.1.5. Italy
      • 15.3.1.6. BENELUX
      • 15.3.1.7. United Kingdom
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Drug
    • 15.3.3. By Infection
    • 15.3.4. By Pathogen
    • 15.3.5. By Route of Administration
    • 15.3.6. By Distribution Channel
  • 15.4. Market Attractiveness Analysis By Region
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Infection
    • 15.4.4. By Pathogen
    • 15.4.5. By Route of Administration
    • 15.4.6. By Distribution Channel
  • 15.5. Market trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Infection
        • 15.8.1.2.3. By Pathogen
        • 15.8.1.2.4. By Route of Administration
        • 15.8.1.2.5. By Distribution Channel
    • 15.8.2. France Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Infection
        • 15.8.2.2.3. By Pathogen
        • 15.8.2.2.4. By Route of Administration
        • 15.8.2.2.5. By Distribution Channel
    • 15.8.3. Spain Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Infection
        • 15.8.3.2.3. By Pathogen
        • 15.8.3.2.4. By Route of Administration
        • 15.8.3.2.5. By Distribution Channel
    • 15.8.4. Russia Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug
        • 15.8.4.2.2. By Infection
        • 15.8.4.2.3. By Pathogen
        • 15.8.4.2.4. By Route of Administration
        • 15.8.4.2.5. By Distribution Channel
    • 15.8.5. Italy Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug
        • 15.8.5.2.2. By Infection
        • 15.8.5.2.3. By Pathogen
        • 15.8.5.2.4. By Route of Administration
        • 15.8.5.2.5. By Distribution Channel
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug
        • 15.8.6.2.2. By Infection
        • 15.8.6.2.3. By Pathogen
        • 15.8.6.2.4. By Route of Administration
        • 15.8.6.2.5. By Distribution Channel
    • 15.8.7. United Kingdom Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug
        • 15.8.7.2.2. By Infection
        • 15.8.7.2.3. By Pathogen
        • 15.8.7.2.4. By Route of Administration
        • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 16.1. Introduction / Key Findings
  • 16.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug
    • 16.3.3. By Infection
    • 16.3.4. By Pathogen
    • 16.3.5. By Route of Administration
    • 16.3.6. By Distribution Channel
  • 16.4. Market Attractiveness Analysis By Region
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Infection
    • 16.4.4. By Pathogen
    • 16.4.5. By Route of Administration
    • 16.4.6. By Distribution Channel
  • 16.5. Market trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Infection
        • 16.8.1.2.3. By Pathogen
        • 16.8.1.2.4. By Route of Administration
        • 16.8.1.2.5. By Distribution Channel
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Infection
        • 16.8.2.2.3. By Pathogen
        • 16.8.2.2.4. By Route of Administration
        • 16.8.2.2.5. By Distribution Channel
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug
        • 16.8.3.2.2. By Infection
        • 16.8.3.2.3. By Pathogen
        • 16.8.3.2.4. By Route of Administration
        • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 17.1. Introduction / Key Findings
  • 17.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Thailand
      • 17.3.1.4. Philippines
      • 17.3.1.5. Malaysia
      • 17.3.1.6. Vietnam
      • 17.3.1.7. Rest of South Asia
    • 17.3.2. By Drug
    • 17.3.3. By Infection
    • 17.3.4. By Pathogen
    • 17.3.5. By Route of Administration
    • 17.3.6. By Distribution Channel
  • 17.4. Market Attractiveness Analysis By Region
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Infection
    • 17.4.4. By Pathogen
    • 17.4.5. By Route of Administration
    • 17.4.6. By Distribution Channel
  • 17.5. Market trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug
        • 17.8.1.2.2. By Infection
        • 17.8.1.2.3. By Pathogen
        • 17.8.1.2.4. By Route of Administration
        • 17.8.1.2.5. By Distribution Channel
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug
        • 17.8.2.2.2. By Infection
        • 17.8.2.2.3. By Pathogen
        • 17.8.2.2.4. By Route of Administration
        • 17.8.2.2.5. By Distribution Channel
    • 17.8.3. Thailand Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug
        • 17.8.3.2.2. By Infection
        • 17.8.3.2.3. By Pathogen
        • 17.8.3.2.4. By Route of Administration
        • 17.8.3.2.5. By Distribution Channel
    • 17.8.4. Philippines Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug
        • 17.8.4.2.2. By Infection
        • 17.8.4.2.3. By Pathogen
        • 17.8.4.2.4. By Route of Administration
        • 17.8.4.2.5. By Distribution Channel
    • 17.8.5. Malaysia Market Analysis
      • 17.8.5.1. Introduction
      • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.5.2.1. By Drug
        • 17.8.5.2.2. By Infection
        • 17.8.5.2.3. By Pathogen
        • 17.8.5.2.4. By Route of Administration
        • 17.8.5.2.5. By Distribution Channel
    • 17.8.6. Vietnam Market Analysis
      • 17.8.6.1. Introduction
      • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.6.2.1. By Drug
        • 17.8.6.2.2. By Infection
        • 17.8.6.2.3. By Pathogen
        • 17.8.6.2.4. By Route of Administration
        • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 18.1. Introduction / Key Findings
  • 18.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug
    • 18.3.3. By Infection
    • 18.3.4. By Pathogen
    • 18.3.5. By Route of Administration
    • 18.3.6. By Distribution Channel
  • 18.4. Market Attractiveness Analysis By Region
    • 18.4.1. By Country
    • 18.4.2. By Drug
    • 18.4.3. By Infection
    • 18.4.4. By Pathogen
    • 18.4.5. By Route of Administration
    • 18.4.6. By Distribution Channel
  • 18.5. Market trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug
        • 18.8.1.2.2. By Infection
        • 18.8.1.2.3. By Pathogen
        • 18.8.1.2.4. By Route of Administration
        • 18.8.1.2.5. By Distribution Channel
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug
        • 18.8.2.2.2. By Infection
        • 18.8.2.2.3. By Pathogen
        • 18.8.2.2.4. By Route of Administration
        • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 19.1. Introduction / Key Findings
  • 19.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019 - 2024
  • 19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. Egypt
      • 19.3.1.4. Israel
      • 19.3.1.5. South Africa
      • 19.3.1.6. Northern Africa
      • 19.3.1.7. Rest of Middle East and Africa
    • 19.3.2. By Drug
    • 19.3.3. By Infection
    • 19.3.4. By Pathogen
    • 19.3.5. By Route of Administration
    • 19.3.6. By Distribution Channel
  • 19.4. Market Attractiveness Analysis By Region
    • 19.4.1. By Country
    • 19.4.2. By Drug
    • 19.4.3. By Infection
    • 19.4.4. By Pathogen
    • 19.4.5. By Route of Administration
    • 19.4.6. By Distribution Channel
  • 19.5. Market trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug
        • 19.8.1.2.2. By Infection
        • 19.8.1.2.3. By Pathogen
        • 19.8.1.2.4. By Route of Administration
        • 19.8.1.2.5. By Distribution Channel
    • 19.8.2. Turkiye Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug
        • 19.8.2.2.2. By Infection
        • 19.8.2.2.3. By Pathogen
        • 19.8.2.2.4. By Route of Administration
        • 19.8.2.2.5. By Distribution Channel
    • 19.8.3. Egypt Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug
        • 19.8.3.2.2. By Infection
        • 19.8.3.2.3. By Pathogen
        • 19.8.3.2.4. By Route of Administration
        • 19.8.3.2.5. By Distribution Channel
    • 19.8.4. Israel Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug
        • 19.8.4.2.2. By Infection
        • 19.8.4.2.3. By Pathogen
        • 19.8.4.2.4. By Route of Administration
        • 19.8.4.2.5. By Distribution Channel
    • 19.8.5. South Africa Market Analysis
      • 19.8.5.1. Introduction
      • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.5.2.1. By Drug
        • 19.8.5.2.2. By Infection
        • 19.8.5.2.3. By Pathogen
        • 19.8.5.2.4. By Route of Administration
        • 19.8.5.2.5. By Distribution Channel
    • 19.8.6. Northern Africa Market Analysis
      • 19.8.6.1. Introduction
      • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.6.2.1. By Drug
        • 19.8.6.2.2. By Infection
        • 19.8.6.2.3. By Pathogen
        • 19.8.6.2.4. By Route of Administration
        • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players (%)
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint of Players
    • 20.3.2. Product Footprint of Players
    • 20.3.3. Channel Footprint of Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Key Development Analysis
  • 21.3. Branding and Promotional Strategies, By Key Players
  • 21.4. Competition Deep Dive
    • 21.4.1. Pfizer Inc.
      • 21.4.1.1. Overview
      • 21.4.1.2. Product Portfolio
      • 21.4.1.3. Key Financials
      • 21.4.1.4. Sales Footprint
      • 21.4.1.5. SWOT Analysis
      • 21.4.1.6. Strategy Overview
        • 21.4.1.6.1. Marketing Strategies
        • 21.4.1.6.2. Channel Strategies
        • 21.4.1.6.3. Product Strategies
    • 21.4.2. Novartis AG
      • 21.4.2.1. Overview
      • 21.4.2.2. Product Portfolio
      • 21.4.2.3. Key Financials
      • 21.4.2.4. Sales Footprint
      • 21.4.2.5. SWOT Analysis
      • 21.4.2.6. Strategy Overview
        • 21.4.2.6.1. Marketing Strategies
        • 21.4.2.6.2. Channel Strategies
        • 21.4.2.6.3. Product Strategies
    • 21.4.3. Mylan N.V.
      • 21.4.3.1. Overview
      • 21.4.3.2. Product Portfolio
      • 21.4.3.3. Key Financials
      • 21.4.3.4. Sales Footprint
      • 21.4.3.5. SWOT Analysis
      • 21.4.3.6. Strategy Overview
        • 21.4.3.6.1. Marketing Strategies
        • 21.4.3.6.2. Channel Strategies
        • 21.4.3.6.3. Product Strategies
    • 21.4.4. Teva Pharmaceuticals
      • 21.4.4.1. Overview
      • 21.4.4.2. Product Portfolio
      • 21.4.4.3. Key Financials
      • 21.4.4.4. Sales Footprint
      • 21.4.4.5. SWOT Analysis
      • 21.4.4.6. Strategy Overview
        • 21.4.4.6.1. Marketing Strategies
        • 21.4.4.6.2. Channel Strategies
        • 21.4.4.6.3. Product Strategies
    • 21.4.5. Merck & Co.
      • 21.4.5.1. Overview
      • 21.4.5.2. Product Portfolio
      • 21.4.5.3. Key Financials
      • 21.4.5.4. Sales Footprint
      • 21.4.5.5. SWOT Analysis
      • 21.4.5.6. Strategy Overview
        • 21.4.5.6.1. Marketing Strategies
        • 21.4.5.6.2. Channel Strategies
        • 21.4.5.6.3. Product Strategies
    • 21.4.6. Eli Lilly & Company
      • 21.4.6.1. Overview
      • 21.4.6.2. Product Portfolio
      • 21.4.6.3. Key Financials
      • 21.4.6.4. Sales Footprint
      • 21.4.6.5. SWOT Analysis
      • 21.4.6.6. Strategy Overview
        • 21.4.6.6.1. Marketing Strategies
        • 21.4.6.6.2. Channel Strategies
        • 21.4.6.6.3. Product Strategies
    • 21.4.7. AstraZeneca plc.
      • 21.4.7.1. Overview
      • 21.4.7.2. Product Portfolio
      • 21.4.7.3. Key Financials
      • 21.4.7.4. Sales Footprint
      • 21.4.7.5. SWOT Analysis
      • 21.4.7.6. Strategy Overview
        • 21.4.7.6.1. Marketing Strategies
        • 21.4.7.6.2. Channel Strategies
        • 21.4.7.6.3. Product Strategies
    • 21.4.8. Lupin Limited
      • 21.4.8.1. Overview
      • 21.4.8.2. Product Portfolio
      • 21.4.8.3. Key Financials
      • 21.4.8.4. Sales Footprint
      • 21.4.8.5. SWOT Analysis
      • 21.4.8.6. Strategy Overview
        • 21.4.8.6.1. Marketing Strategies
        • 21.4.8.6.2. Channel Strategies
        • 21.4.8.6.3. Product Strategies
    • 21.4.9. Dr Reddys Laboratories
      • 21.4.9.1. Overview
      • 21.4.9.2. Product Portfolio
      • 21.4.9.3. Key Financials
      • 21.4.9.4. Sales Footprint
      • 21.4.9.5. SWOT Analysis
      • 21.4.9.6. Strategy Overview
        • 21.4.9.6.1. Marketing Strategies
        • 21.4.9.6.2. Channel Strategies
        • 21.4.9.6.3. Product Strategies
    • 21.4.10. Aurobindo Pharma Ltd
      • 21.4.10.1. Overview
      • 21.4.10.2. Product Portfolio
      • 21.4.10.3. Key Financials
      • 21.4.10.4. Sales Footprint
      • 21.4.10.5. SWOT Analysis
      • 21.4.10.6. Strategy Overview
        • 21.4.10.6.1. Marketing Strategies
        • 21.4.10.6.2. Channel Strategies
        • 21.4.10.6.3. Product Strategies
    • 21.4.11. GSK plc.
      • 21.4.11.1. Overview
      • 21.4.11.2. Product Portfolio
      • 21.4.11.3. Key Financials
      • 21.4.11.4. Sales Footprint
      • 21.4.11.5. SWOT Analysis
      • 21.4.11.6. Strategy Overview
        • 21.4.11.6.1. Marketing Strategies
        • 21.4.11.6.2. Channel Strategies
        • 21.4.11.6.3. Product Strategies
    • 21.4.12. Sun Pharmaceutical Industries Ltd.
      • 21.4.12.1. Overview
      • 21.4.12.2. Product Portfolio
      • 21.4.12.3. Key Financials
      • 21.4.12.4. Sales Footprint
      • 21.4.12.5. SWOT Analysis
      • 21.4.12.6. Strategy Overview
        • 21.4.12.6.1. Marketing Strategies
        • 21.4.12.6.2. Channel Strategies
        • 21.4.12.6.3. Product Strategies
    • 21.4.13. Cipla ltd.
      • 21.4.13.1. Overview
      • 21.4.13.2. Product Portfolio
      • 21.4.13.3. Key Financials
      • 21.4.13.4. Sales Footprint
      • 21.4.13.5. SWOT Analysis
      • 21.4.13.6. Strategy Overview
        • 21.4.13.6.1. Marketing Strategies
        • 21.4.13.6.2. Channel Strategies
        • 21.4.13.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology